# Cardiac Metabolic Modulator Treatment for Improvement of Diastolic Function in Patients With Coronary Heart Disease

> **NCT03887013** · PHASE4 · UNKNOWN · sponsor: **China National Center for Cardiovascular Diseases** · enrollment: 226 (estimated)

## Conditions studied

- Coronary Heart Disease
- Diastolic Dysfunction

## Interventions

- **DRUG:** Trimetazidine

## Key facts

- **NCT ID:** NCT03887013
- **Lead sponsor:** China National Center for Cardiovascular Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-25
- **Primary completion:** 2020-10
- **Final completion:** 2020-12
- **Target enrollment:** 226 (ESTIMATED)
- **Last updated:** 2019-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03887013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03887013, "Cardiac Metabolic Modulator Treatment for Improvement of Diastolic Function in Patients With Coronary Heart Disease". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03887013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*